Opened 79 days ago
Closes 30 November 2021
Trial Aim Description
Two new drug trials for people with Huntington’s disease, called PRECISION-HD1 and PRECISION-HD2. Each study tests a separate Huntingtin-lowering (also known as gene silencing) agent. They are run by a company called Wave Life Sciences based in Massachusetts, USA.
Trial Eligibility Requirements
Participants must be between the ages of 25-65, have early stage Huntington’s disease, and meet additional criteria. The studies involve lumbar punctures, MRI scans, assessments and questionnaires.
Principal Investigator: Dr Carolyn Orr
Enquiries Email: email@example.com